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Background: Unresectable gastric cancer is associated with poor outcomes, with few treatment options
available after failure of cytotoxic chemotherapy. Clinical trials of targeted therapies have generally shown no
survival benefit in gastric cancer, with the exceptions of the antibodies ramucirumab (anti-VEGFR2) and trastuzumab
(anti-HER2/neu). Given the efficacy of the multikinase inhibitor regorafenib in other gastrointestinal tumors, we
investigated its potential in gastric cancer.
Methods: The antitumor activity of oral regorafenib was assessed in eight murine patient-derived gastric cancer
xenograft models. Dose–response experiments assessed the efficacy and tolerability of oral regorafenib 5, 10, and
15 mg/kg/day in two models, with 10 mg/kg/day selected for further investigation in all eight models. Tumor weight
and volume was monitored during treatment; tumor cell proliferation, angiogenesis, apoptosis, and intracellular
signaling were assessed using immunohistochemistry and Western blotting of total tumor lysates at the end of
treatment.
Results: Regorafenib showed dose-dependent inhibition of tumor growth and was well tolerated, with no significant
decreases in bodyweight or evident toxicity. Regorafenib 10 mg/kg/day significantly inhibited tumor growth in all
eight models (72 to 96 %; all p < 0.01), resulting in reduced tumor weight versus vehicle controls. Regorafenib reduced
tumor angiogenesis 3- to 11-fold versus controls in all models (all p < 0.05), reduced tumor proliferation 2- to 5-fold in
six of the eight models (all p < 0.05), and induced apoptosis in seven models.
Conclusion: Regorafenib was effective in patient-derived models of gastric cancer of different histological subtypes,
with inhibition of tumor growth, angiogenesis, and tumor-cell proliferation observed in almost all models. These
findings are consistent with the observed activity of regorafenib in preclinical models of other gastrointestinal tumors,
and support further clinical investigation in gastric cancer.
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Gastric cancer is the fifth most common malignancy
worldwide, with an estimated 950,000 new cases in 2012;
approximately two thirds of cases occur in men [1, 2].
Mortality statistics are even more striking, with more than
720,000 deaths due to gastric cancer estimated to occur
each year, making it the third most common cause of
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Eastern Asia, particularly China, accounting for 50 % of
patients [1, 2]. A number of risk factors for the develop-
ment of gastric cancer have been identified, the most im-
portant of which is infection with Helicobacter pylori [3].
Surgical resection is the first choice of treatment for
early-stage gastric cancer [4]; however, many cases are
locally advanced or metastatic at the time of diagnosis
and are thus unresectable [5]. Although a number of
cytotoxic agents have been found effective in this indica-
tion, treatment options for patients whose diseaseis distributed under the terms of the Creative Commons Attribution 4.0
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an overall 5-year survival rate of just 28 % [5].
The presence of gain-of-function mutations affecting
receptor tyrosine kinases (RTKs) is associated with poor
prognosis in patients with gastric cancer [6, 7]. In an
effort to provide additional treatment options in this
patient group, a variety of targeted therapies have been
investigated. Potential molecular targets identified in-
clude RTKs involved in angiogenesis and tumor prolif-
eration, such as vascular endothelial growth factor
(VEGF), angiopoietin, platelet-derived growth factor
(PDGF), fibroblast growth factor (FGF) receptors, and
HER2/neu [6, 8–10]. Interestingly, some of the recep-
tors identified as potential targets have overlapping
intracellular signal transduction cascades, notably the
PI3K/AKT/mTOR and MAPK pathways [11–14]. Acti-
vation of these signaling cascades is associated with in-
creased tumor-cell proliferation and survival, as well as
inhibition of apoptosis [15, 16].
Clinical trials of targeted therapies in gastric cancer
have met with varying levels of success. Studies of beva-
cizumab, cetuximab, panitumumab, and everolimus have
failed to show a significant survival benefit versus vary-
ing control treatments, and a phase II trial of sunitinib
failed to meet its primary endpoint [17–22]. However,
the anti-VEGF receptor 2 (VEGFR2) antibody ramuciru-
mab improved survival compared with placebo in a
phase III trial [23] and has been approved for advanced
gastric cancer by the US Food and Drug Administration
and the European Medicines Agency. Addition of the
anti-HER2/neu monoclonal antibody trastuzumab to
chemotherapy has also been shown to provide benefit
versus chemotherapy alone in patients with HER2/neu-
positive tumors [24].
Regorafenib is a multikinase inhibitor with activity at a
range of protein kinases involved in oncogenesis (KIT,
RET, and RAF), angiogenesis (VEGFR1–3 and TIE2),
and maintenance of the tumor microenvironment
(PDGFR and FGFR) [25]. Regorafenib has demonstrated
efficacy in phase III trials in patients with metastatic
colorectal cancer (CRC) [26, 27] and advanced gastro-
intestinal stromal tumors (GIST) [28] and has been ap-
proved in these indications in a number of countries.
Given the wide range of kinases inhibited by regorafenib
and its clinical efficacy in other gastrointestinal tumors,
we investigated its antitumor activity in patient-derived
xenograft (PDX) models of gastric cancer.
Methods
Reagents
Antibodies against Bim, cleaved poly(ADP ribose) polymer-
ase (PARP), AKT, p-Ser473 AKT, p-Thr202/Tyr204 ERK1/2,
p-Ser10 histone H3, S6R, p-Ser235/236 S6R, Rb, p-Ser780 Rb,
p-Ser807/811 Rb, VEGFR2, p-Tyr951 VEGFR2, p90RSK1–3,p-Thr359/Ser363 p90RSK, p70S6K, p-Thr421/Ser424 p70S6K,
p-Tyr15 CDC-2, p-Thr14/Tyr15 CDK-2, 4EBP1, p-Thr70
4EBP1, and TIE2 were obtained from Cell Signaling Tech-
nology. Antibodies against BAD, p21, CD-31, CDK-2,
CDK-4, CDC-2, cyclin B1, ERK1/2, p27, survivin, and α-
tubulin were obtained from Santa Cruz. Triton X100,
NaCl, and NP-40 were obtained from Merck KGaA.
EDTA, sodium orthovanadate, and Tris-base were from
Sigma-Aldrich. Tween-20 was purchased from Promega
Corporation.
Regorafenib was dissolved in dimethyl sulfoxide to
create a stock solution with a concentration of 100 mg/
mL. To achieve the solution with the final concentration
for administration, 0.1 mL of the regorafenib stock
solution (or dimethyl sulfoxide for the control group)
was further diluted in vehicle (4 mL of polyethylene
glycol 300 and 3.9 mL of 30 % Captisol [purchased
from CyDex] in water).
Patient-derived xenografts
Animal experiments were approved by the ethics board at
the National Cancer Centre of Singapore and Singapore
General Hospital. All mice were maintained according to
the Guide for Care and Use of Laboratory Animals, pub-
lished by the US National Institutes of Health [29]. Ani-
mals were provided with sterilized food and water ad
libitum, and were housed in negative-pressure isolators
with 12-h light/dark cycles.
Xenograft experiments were performed with male se-
vere combined immunodeficiency (SCID) mice (Animal
Resources Centre). Eight patient-derived gastric cancer
PDX models (GC09-0109, GC28-1107, GC22-0808,
GC30-0309, GC10-0608, GC17-0409, GC05-0208B, and
GC23-0909) were used to establish subcutaneous tumors
in mice aged 9–10 weeks. Tumor model histology and
mutation status are shown in Additional file 1: Table S1.
Antitumor activity in vivo
For dose response and tolerability analyses, mice bearing
GC09-0109 and GC28-1107 tumor xenografts were
given oral vehicle or regorafenib 5, 10, or 15 mg/kg/day.
Each treatment group comprised 15 or 16 mice. Treat-
ment was started when tumors reached approximately
150 to 200 mm3. Tumors were measured bidimension-
ally and their volume was calculated using the formula:
(length) × (width2) × (π/6). Mice were killed at the end of
the study; tumor weight and bodyweight were recorded,
and tumors were preserved for further analysis.
For the assessment of antitumor activity in additional
tumor models, xenografts were grown subcutaneously in
mice (14 to 20 mice per group) to a size of approxi-
mately 200 to 300 mm3. Mice were then given daily oral
doses of either 200 μL of vehicle or regorafenib 10 mg/
kg, with the last dose given 2 h before death. Tumor
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periments. A portion of each tumor was fixed in parafor-
maldehyde and embedded in paraffin, with further
portions snap frozen for tumor lysate generation and
cryopreserved for immunohistochemistry (IHC).
Western blot analysis
To investigate changes in levels of phosphorylated and
total proteins identified as targets of regorafenib or with
roles in tumor cell proliferation, apoptosis, cell cycle
regulation, and survival, three to four randomly selected
independent tumors from vehicle and drug-treated mice
were combined and homogenized in lysis buffer (0.5 %
Triton X100; 150 mMol/L NaCl; 10 mMol/L EDTA; 2
mMol/L sodium orthovanadate; 0.5 % NP-40). Protein
concentration was determined by Bio-Rad protein assay
(Bio-Rad Laboratories). Eighty micrograms of total lysate
per tumor sample preparation were analyzed by Western
blot. Blots were incubated with primary antibodies di-
luted in TBST (20 mMol/L Tris, pH 7.6, 150 mMol/L
NaCl and 0.1 % Tween-20) containing 1 % nonfat dry
milk and a 1:7500 dilution of horseradish peroxidase-
conjugated secondary antibodies. All primary antibodies
were then visualized with a chemiluminescent detection
system (Amersham, Pharmacia Biotech).
Immunohistochemistry and histological staining
Fifteen micron sections of optimal cutting temperature
compound-embedded (Tissue-Tek; Sakura Finetek) tu-
mors were immunostained with anti-CD31 antibodies to
assess microvessel density (MVD). To quantify MVD,
the number of immunostained vessels in ten 0.159 mm2
fields at a magnification of × 100 from ten randomly se-
lected tumors in each group was counted. Five microm-
eter sections of paraffin-embedded tumor tissue were
immunostained with anti-p-Ser10 histone H3 or cleaved
PARP antibodies to assess tumor-cell proliferation and
apoptosis, respectively, based on the percentage of p-
Ser10 histone H3-positive and cleaved PARP-positive
cells per ≥500 cell region, respectively. Three tumors per
treatment and four regions per tumor were analyzed for
tumor cell proliferation and apoptosis. Induction of
apoptosis was defined as a two-fold or greater increase
in the proportion of cells identified as cleaved PARP-
positive in tumors from regorafenib-treated mice com-
pared with tumors from vehicle-treated animals. Images
were recorded using an Olympus BX60 microscope
equipped with an Olympus DP11 camera. All experi-
ments were performed in triplicate.
Tumor necrosis was assessed by microscopic examin-
ation of hematoxylin and eosin (H&E)-stained tumor
sections, with ten random fields examined at a × 100
magnification. Tumor necrosis was only qualitatively
assessed.Statistical analysis
Differences in tumor weight at death, p-Ser10 histone
H3 index, mean MVD, and cleaved PARP-positive
cells were compared by analysis of variance or Student’s
t-test. Significance was established at p < 0.05 for all
statistical analyses.
Results
Regorafenib inhibits growth of gastric cancer xenografts
in a dose-dependent manner
Regorafenib 5, 10, or 15 mg/kg/day was administered for
22 days to mice with GC09-0109 and GC28-1107 xeno-
grafts, with tumor growth inhibition assessed by compari-
son of the tumor weights of vehicle- and regorafenib-
treated animals. In the GC09-0109 model, regorafenib was
associated with 81 to 88 % inhibition of tumor growth
compared with vehicle-treated animals (n = 15 per group;
Fig. 1a), while the GC28-1107 model showed 72 to 88 %
inhibition of tumor growth compared with vehicle-treated
controls (n = 16 per group; Additional file 2: Figure S1a).
Tumors from regorafenib-treated mice weighed dose-
proportionately less than those from vehicle-treated mice
(all p < 0.05; Fig. 1b and Additional file 2: Figure S1b). No
significant loss of bodyweight (Fig. 1c and Additional file 2:
Figure S1c) or signs of toxicity were observed in any of the
treatment groups.
On the basis of the observed tumor growth inhibition
and tolerability profile of regorafenib in the GC28-
1107 xenograft line, and consistent with previous studies
[25, 30], the 10 mg/kg/day dose was selected for further
investigation in other gastric cancer xenograft lines.
Regorafenib 10 mg/kg/day inhibits tumor growth in
gastric cancer xenograft models
Regorafenib 10 mg/kg/day inhibited tumor growth com-
pared with vehicle in all gastric cancer xenograft models,
with reductions in tumor weight of 72 to 96 % (all p <
0.01; Fig. 2, Additional file 3: Figure S2, and Table 1).
The potent antitumor activity appeared to be independ-
ent of the histological subtypes of the tumor models,
which encompass tumors of intestinal, diffuse, mixed,
and tubular origin (Additional file 1: Table S1). Although
the study had a small sample size, there appeared to be
no correlation between mutational status, including
KRAS and PDGFR-α mutation status, and tumor growth
inhibition (Additional file 1: Table S1). As in the dose–
response experiments, no significant loss of bodyweight
or signs of toxicity were observed in any of the treat-
ment groups (data not shown).
Regorafenib reduces tumor angiogenesis
Regorafenib 10 mg/kg/day significantly reduced MVD in
all gastric cancer xenograft models compared with ve-
hicle (all p < 0.05), as assessed by binding of anti-CD31
Fig. 1 Regorafenib dose-dependently inhibits growth of patient-derived xenografts. The effects of regorafenib 5, 10, and 15 mg/kg/day on tumor
growth inhibition (a), tumor weight (b), and bodyweight (c) in xenograft model GC09-0109 are shown. Data are mean ± standard error (*, p < 0.01;
**, p < 0.001; N.S., not significant)
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Fig. 2 Regorafenib 10 mg/kg/day significantly inhibits growth of patient-derived xenografts. The effects of regorafenib 10 mg/kg/day on tumor
growth inhibition (a, b, and c), tumor weight (d, e, and f), and representative tumors (g, h, and i) are demonstrated in xenograft models GC17-0409,
GC28-1107, and GC09-0109. Data are mean ± standard error (*, p < 0.001)
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were three- to eleven-fold lower than in vehicle-treated
mice (Fig. 3 and Table 2). Tumors from regorafenib-
treated mice generally had a pale appearance, consistent
with reduced MVD and poor vascularization (Fig. 2g–i).
IHC of the GC05-0208B model showed that TIE2 was
expressed in host-derived stromal cells and blood ves-
sels, but not in tumor cells. TIE2 immunostaining did
not appear to differ between regorafenib- and vehicle-
treated tumors (Additional file 4: Figure S3).
Analysis of changes in VEGFR2 expression in pooled
tumor lysates produced heterogeneous results, with re-
duced total or p-Tyr951 VEGFR2 levels in GC17-0409
and GC28-1107 tumors, respectively, and no apparent
changes in p-Tyr951 VEGFR2 levels in GC09-0109 tu-
mors (Fig. 4). These disparate results may be related to
histological or spatio-temporal differences between
VEGFR2 inhibition and reductions in MVD.
Regorafenib inhibits tumor cell proliferation
Tumor cell proliferation, based on the proportion of p-
Ser10 histone H3-positive cells, was two- to five-foldlower in six xenograft models after treatment with rego-
rafenib 10 mg/kg/day than in tumors from vehicle-
treated mice (p < 0.05; Fig. 3 and Table 2).
Pooled tumor lysates from regorafenib- and vehicle-
treated mice were analyzed for the effects of regorafenib
on selected proteins involved in the MAPK and AKT/
mTOR signaling pathways and for selected proteins in-
volved in the cell cycle (Fig. 4). No overt effects were ob-
served on p-ERK levels in the GC17-0409, GC28-1107,
and GC09-0109 models. Analysis of p-AKT and some of
its downstream target proteins produced variable results.
Whereas no changes were observed in the GC09-0109
model, levels of p-Ser473 AKT, p-Thr359/Ser363 p90RSK, p-
Thr421/Ser424 p70S6K, p-Ser235/236 S6R, and p-Thr70
4EBP1 appeared to be consistently reduced in the GC17-
0409 and GC28-1107 models, suggesting that the AKT/
mTOR pathway plays a role in the growth-inhibiting
effects of regorafenib in these models. Moderate or no
effects were observed on levels of cell cycle proteins such
as p-Tyr15 CDC-2, p-Thr14/p-Tyr15 CDK-2, p-Ser780 RB,
and p-Ser807/811 RB, indicating that these mechanisms do
not play a role in the antiproliferative effect of regorafenib.
Table 1 Regorafenib inhibits the growth of patient-derived
gastric cancer xenograft models








GC09-0109 Vehicle 1.14 (0.12)
Reg 5 0.21 (0.03) 81.4 <0.001
Reg 10 0.17 (0.02) 84.9 <0.001
Reg 15 0.14 (0.02) 88.1 <0.001
GC28-1107 Vehicle 1.72 (0.16)
Reg 5 0.48 (0.06) 72.4 <0.001
Reg 10 0.39 (0.06) 77.6 <0.001
Reg 15 0.21 (0.03) 88.0 <0.001
GC09-0109 Vehicle 0.92 (0.05)
Reg 10 0.14 (0.01) 84.9 <0.01
GC22-0808 Vehicle 2.55 (0.27)
Reg 10 0.11 (0.01) 95.9 <0.001
GC17-0409 Vehicle 2.03 (0.22)
Reg 10 0.36 (0.05) 82.4 <0.001
GC10-0608 Vehicle 3.11 (0.35)
Reg 10 0.31 (0.04) 90.0 <0.001
GC28-1107 Vehicle 1.40 (0.12)
Reg 10 0.40 (0.02) 71.5 <0.001
GC23-0909 Vehicle 1.73 (0.11)
Reg 10 0.22 (0.02) 87.0 <0.001
GC30-0309 Vehicle 3.48 (0.28)
Reg 10 0.59 (0.07) 83.0 <0.001
GC05-0208B Vehicle 2.17 (0.10)
Reg 10 0.49 (0.03) 77.6 <0.001
Reg 5: regorafenib 5 mg/kg/day; Reg 10: regorafenib 10 mg/kg/day; Reg 15:
regorafenib 15 mg/kg/day
aTumor growth inhibition based on the difference in tumor weight between
vehicle and regorafenib
Huynh et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:132 Page 6 of 10Regorafenib induces apoptosis and central necrosis
Regorafenib 10 mg/kg/day induced apoptosis in seven of
the eight gastric cancer xenograft models (all p < 0.05
versus tumors from vehicle-treated animals; Table 2 and
Fig. 3) measured by detection of cells staining positive
for cleaved PARP on IHC. Differences in the number of
cleaved PARP-positive cells in tumors from regorafenib-
versus vehicle-treated animals ranged from approximately
two-fold to more than 75-fold (Table 2). Western blot of
pooled tumor lysate confirmed that, compared with tu-
mors from vehicle-treated mice, tumors from regorafenib-
treated mice consistently showed elevated levels of cleaved
PARP in the GC17-0409, GC28-1107, and GC09-0109
models, although the levels of elevation were variable
(Fig. 4), coupled with decreased levels of the antiapoptotic
protein survivin. No obvious changes in levels of the proa-
poptotic protein BAD were detected.In addition to induction of apoptosis, central necrosis
was observed in H&E-stained sections of tumors from
all eight xenograft models following treatment with re-
gorafenib (Fig. 3 and data not shown). Areas of necrosis
were preferentially associated with apoptosis.
Discussion
Expression of VEGF is strongly correlated with tumor
progression and poor prognosis in gastrointestinal malig-
nancies, including gastric cancer [31], with an association
between VEGF expression, increased MVD, and decreased
survival established in previous studies [10, 32]. Preclinical
studies of VEGFR-targeting agents in gastric cancer have
shown significant antitumor effects [33, 34], and a clinical
trial with the VEGFR2 antibody ramucirumab monother-
apy has demonstrated survival benefits over placebo
for patients with advanced gastric cancer, validating
VEGFR2 as a relevant therapeutic target in gastric
cancer [23]. However, overall survival gains after
ramucirumab treatment were moderate and the re-
sponse rate was low [23], which indicates a need for
additional antiangiogenic approaches.
This study was performed to assess the antitumor activ-
ity of the multikinase inhibitor regorafenib, a known potent
inhibitor of VEGFR kinases in gastric cancer xenografts,
and to investigate the underlying antitumor mechanisms.
Our findings show that all eight patient-derived xenograft
models investigated in the current study respond favorably
to regorafenib, with tumor growth inhibition of 72 to 96 %
at a dose of 10 mg/kg/day in a variety of histological sub-
types. At this dose, regorafenib exposure and Cmax in mice
are comparable to those observed in humans after 21 days
of treatment with regorafenib 160 mg/day [35], a dose
which has demonstrated efficacy in patients with CRC and
GIST [26–28].
Analysis of the mechanisms by which regorafenib
inhibited tumor growth inhibition showed a pronounced
antiangiogenic effect in xenografts from all regorafenib-
treated mice, as measured by MVD reduction versus
vehicle-treated animals. Tumors from vehicle-treated an-
imals were well vascularized, as judged by both mea-
sured MVD and visual appearance (Figs. 2 and 3 and
Table 2). Elevated MVD has previously been detected in
clinical samples of diffuse- versus intestinal-type tumors
[10, 32], which was not apparent in our vehicle-treated
xenografts. A stronger antiangiogenic effect with regorafe-
nib treatment was noticed in intestinal than in diffuse-
type tumor models, but did not translate into differences
in antitumor activity. Consistent with the antiangiogenic
effects detected by IHC, levels of phosphorylated or total
VEGFR2 protein were reduced in pooled tumor lysates
from some models (Fig. 4).
Regorafenib also inhibited cell proliferation, as shown
by the significant decrease in the proportion of p-Ser10
Fig. 3 Regorafenib 10 mg/kg/day inhibits tumor angiogenesis and tumor cell proliferation, and induces apoptosis. The effects of regorafenib on
tumor angiogenesis (CD31 expression), cell proliferation (p-Ser10 histone H3 expression), and apoptosis (cleaved PARP expression) are demonstrated in
xenografts GC17-0409 (diffuse histology; a), GC28-1107 (more intestinal; b), and GC09-0109 (tubular histology; c). Dotted lines denote areas of necrosis.
PARP: poly(ADP ribose) polymerase
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which were of intestinal origin. However, there was no
correlation between the antiproliferative and antitumor
effects, similar to what was observed with the antiangio-
genic effects. Ser10 of histone H3 is phosphorylated by
mitogen- and stress-activated kinase 1, Aurora B, or
checkpoint kinase 1 [36]; none of these kinases is signifi-
cantly inhibited by regorafenib in biochemical assays
[25], precluding a direct antiproliferative activity of rego-
rafenib by inhibition of Ser10 histone H3 phosphoryl-
ation. In Western blots, no effects were observed on
proteins associated with the cell cycle, such as cyclin-
dependent kinases 2 (Fig. 4), cyclin-dependent kinases 1,
4, and 6 (data not shown), and the RB protein (Fig. 4). Al-
though not systematically analyzed, regulatory proteinsTable 2 Regorafenib 10 mg/kg/day reduces mean microvessel dens
apoptosis (cleaved PARP-positive cells) in patient-derived gastric can
Mean (SE) microvessel densitya Mean (SE) p-histo
Xenograft model Vehicle Reg 10 Fold difference Vehicle Re
GC09-0109 20.0 (6.0) 2.0 (0.5)* 10.0 8.3 (1.6) 2.1
GC28-1107 11.4 (1.8) 2.4 (0.8)* 4.8 4.6 (0.4) 1.4
GC22-0808 23.0 (7.0) 2.1 (0.7)* 11.0 8.9 (2.1) 8.2
GC30-0309 16.0 (4.0) 5.0 (2.0)* 3.2 17.8 (8.0) 5.3
GC10-0608 24.0 (5.0) 2.7 (1.0)* 8.9 10.3 (3.0) 2.1
GC17-0409 28.0 (7.0) 5.0 (1.4)* 5.6 15.3 (5.0) 4.8
GC05-0208B 43.0 (11.0) 4.0 (1.2)* 10.8 4.8 (0.9) 3.1
GC23-0909 16.1 (2.8) 5.2 (1.0)* 3.1 13.9 (2.8) 5.7
PARP: poly-(ADP ribose) polymerase; Reg 10: regorafenib 10 mg/kg/day; SE: standar
*p < 0.05 versus vehicle
aNumber of immunostained vessels in ten 0.159 mm2 fields from ten randomly selesuch as cyclin B1 and the cyclin inhibitors p21 and p27
were not affected (data not shown). Given these find-
ings, more detailed research is required to provide a
molecular explanation for the antiproliferative effect
of regorafenib.
Gastric cancer cell apoptosis was induced by regorafe-
nib through the caspase-mediated mitochondrial path-
way, demonstrated by the increased proportion of
caspase-cleaved PARP-positive tumor cells and elevated
levels of cleaved PARP in tumor lysates (Fig. 4 and
Table 2). The extent of apoptosis induction varied widely
and was strongest in diffuse- and mixed-type tumor
models; however, there was no correlation with tumor
growth inhibition. Small reductions in levels of the anti-
apoptotic protein survivin were consistently observed inity, cell proliferation (p histone H3 Ser10-positive cells) and
cer xenograft models
ne H3 Ser10-positive cells, % Mean (SE) cleaved PARP-positive cells, %
g 10 Fold difference Vehicle Reg 10 Fold difference
(0.7)* 4.0 1.2 (0.5) 2.1 (0.6) 1.8
(0.6)* 3.3 0.3 (0.1) 7.3 (1.5)* 24.3
(1.4) 1.1 2.7 (1.5) 6.8 (2.4)* 2.5
(2.0)* 3.4 1.4 (0.7) 17.2 (4.0)* 12.3
(0.4)* 4.9 0.9 (0.4) 4.8 (1.4)* 5.3
(1.1)* 3.2 0.4 (0.2) 31.0 (10.0)* 77.5
(0.8) 1.5 3.1 (0.9) 9.9 (3.0)* 3.2
(1.7)* 2.4 0.3 (0.1) 7.3 (1.9)* 24.3
d error
cted tumors at a magnification of × 100
Fig. 4 Effects of regorafenib on protein expression and phosphorylation in GC17-0409, GC28-1107, and GC09-0109 xenografts. Western blots were
performed using two pooled lysates of three to four individual tumors each per group
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levels of the proapoptotic protein BAD were not af-
fected. High survivin expression has been correlated
with poor prognosis in gastric cancer [37], suggesting
that regorafenib-induced reductions could contribute to
the antitumor activity of regorafenib. Expression of an-
other proapoptotic protein, PUMA (p53 upregulated
modulator of apoptosis), has also been found to be
downregulated in gastric cancer [38]. PUMA expression
was recently shown to be upregulated by regorafenib in
CRC cells [39], raising the possibility that regorafenib
may have a similar effect in gastric cancer. In light of the
multiple pathways that appear to play a role in apop-
tosis, it may be necessary to take an integrated systems
approach covering the entire apoptosis network, as was
used by Lindner et al. [40], to better understand the role
of apoptosis in the antitumor activity of regorafenib.
The effects of regorafenib on gastric cancer xenografts
in the current study are consistent with the findings of
previous preclinical studies of regorafenib, including
xenograft studies in other gastrointestinal tumor types.
At doses of 10 to 30 mg/kg/day, regorafenib inhibited
tumor growth by up to 75 % versus vehicle in various
CRC tumor models, including subcutaneous xenografts
of the tumor cell line Colo-205, five of seven CRC PDX
models, and an orthotopic CRC model derived from the
murine cell line CT26 [25, 30, 41]. Tumor regression
was also observed in a GIST PDX model [42]. Analysis
of angiogenesis in the CT26, Colo-205, and Co5896
CRC PDX models and the GIST PDX model showed asignificant reduction in tumor vessel area or vessel num-
ber in regorafenib-treated xenografts, assessed by CD31
staining, while no significant change in microvessel area
was observed in the regorafenib-refractory Co8541 CRC
model [25, 30, 41, 42]. These previous results, in
addition to those from the current study, suggest that
antiangiogenesis is one of the main drivers of the antitu-
mor activity of regorafenib in gastrointestinal tumors
such as CRC, GIST, and gastric cancer, with further sup-
port from the observation of central necrosis in all of
the gastric cancer models of this study (Fig. 3 and data
not shown) and in a GIST PDX model [42]. Although
not specifically investigated here, induction of hypoxia
could lead to apoptosis, which would also explain the
apoptotic events observed in this study. Regorafenib has
been shown to induce apoptosis in a murine CT26 CRC
model, with an approximately 18-fold increase in apop-
tosis observed in regorafenib-treated mice compared
with controls [41]; however, no effects were observed in
the GIST PDX model [42].
Conclusion
In summary, regorafenib appears to be effective in PDX
models of gastric cancer, resulting in significant inhib-
ition of tumor growth, angiogenesis, and tumor-cell pro-
liferation, as well as induction of apoptosis. Given these
findings, regorafenib warrants further investigation in
this indication in clinical studies. Indeed, regorafenib
was active in a recent randomized, double-blind,
placebo-controlled phase II trial in patients with
Huynh et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:132 Page 9 of 10refractory advanced esophago-gastric cancer (INTE-
GRATE) [43], with significantly longer progression-free
survival observed in the regorafenib group versus
placebo.
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